The NAD⁺/Sirtuin Pathway Modulates Longevity through Activation of Mitochondrial UPR and FOXO Signaling

Laurent Mouchiroud,1,4 Riekelt H. Houtkooper,1,2,4 Norman Moullan,1 Elena Katsyuba,1 Dongryeol Ryu,1 Carles Cantó,1,5 Adrienne Mottis,1 Young-Suk Jo,1 Mohan Viswanathan,3 Kristina Schoonjans,1 Leonard Guarente,3 and Johan Auwerx1,*

1Laboratory for Integrative and Systems Physiology, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland
2Laboratory Genetic Metabolic Diseases, Academic Medical Center, 1105 AZ Amsterdam, The Netherlands
3Paul F. Glenn Laboratory, Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
4These authors contributed equally to this work
5Present address: Nestlé Institute of Health Sciences, 1015 Lausanne, Switzerland
*Correspondence: admin.auwerx@epfl.ch
http://dx.doi.org/10.1016/j.cell.2013.06.016

SUMMARY

NAD⁺ is an important cofactor regulating metabolic homeostasis and a rate-limiting substrate for sirtuin deacetylases. We show that NAD⁺ levels are reduced in aged mice and Caenorhabditis elegans and that decreasing NAD⁺ levels results in a further reduction in worm lifespan. Conversely, genetic or pharmacological restoration of NAD⁺ prevents age-associated metabolic decline and promotes longevity in worms. These effects are dependent upon the protein deacetylase sir-2.1 and involve the induction of mitonuclear protein imbalance as well as activation of stress signaling via the mitochondrial unfolded protein response (UPRmt) and the nuclear translocation and activation of FOXO transcription factor DAF-16. Our data suggest that augmenting mitochondrial stress signaling through the modulation of NAD⁺ levels may be a target to improve mitochondrial function and prevent or treat age-associated decline.

INTRODUCTION

Alterations in NAD⁺ levels have a powerful metabolic impact because it serves as an obligatory substrate for the deacetylase activity of the sirtuin proteins (Guarente, 2008; Haigis and Sinclair, 2010; Houtkooper et al., 2010a). The best-characterized mammalian sirtuin is SIRT1, which controls mitochondrial function through the deacetylation of targets that include PGC-1α and FOXO (Chalkiadaki and Guarente, 2012; Houtkooper et al., 2012). The administration of NAD⁺ precursors, such as nicotinamide mononucleotide (Yoshino et al., 2011) or nicotinamide riboside (NR) (Cantó et al., 2012), has proven to be an efficient way to increase NAD⁺ levels and SIRT1 activity, improving metabolic homeostasis in mice. Furthermore, the NAD⁺-consuming poly(ADP-ribose) polymerase proteins—with PARP1 and PARP2 representing the main PARP activities in mammals—were classically described as DNA repair proteins (Gibson and Kraus, 2012; Schreiber et al., 2006), but recent studies have linked these proteins to metabolism (Asher et al., 2010; Bai et al., 2011a, 2011b; Erener et al., 2012). Indeed, genetic or pharmacological inactivation of PARP1 increased tissue NAD⁺ levels and activated mitochondrial metabolism (Bai et al., 2011b). An association between PARPs and lifespan has been postulated (Grube and Bürkle, 1992; Mangerich et al., 2010), but a causal role remained unclear. A final line of evidence in support of a role for NAD⁺ in metabolic control came from the deletion of an alternative NAD⁺-consuming protein, CD38, which also led to NAD⁺ accumulation and subsequent SIRT1 activation in mice and proved protective against high-fat diet-induced obesity (Barbosa et al., 2007).

Considering the intimate link between metabolism and longevity (Guarente, 2008; Houtkooper et al., 2010b), we hypothesized that increasing NAD⁺ levels may be sufficient to increase mitochondrial activity and extend lifespan (Houtkooper and Auwerx, 2012). Here, we show how supplementation of PARP inhibitors or NAD⁺ precursors led to improved mitochondrial homeostasis through the activation of the worm sirtuin homolog, sir-2.1. This improvement involved the disturbed balance between OXPHOS subunits encoded by mitochondrial DNA (mtDNA) and nuclear DNA (nDNA), a state we termed mitonuclear protein imbalance. This associates with the activation of the mitochondrial unfolded protein response (UPRmt)—a mitochondrial proteostasis pathway promoting longevity (Durieux et al., 2011; Yoneda et al., 2004; Zhao et al., 2002)—and subsequent translocation and activation of the FOXO transcription factor daf-16—triggering an antioxidant protection program (Honda and Honda, 1999). Together, our results expose a temporal regulation network for sirtuins on eukaryotic lifespan and pharmacological approaches to control this pathway and prevent age-related physiological decline.
RESULTS

Disturbed NAD⁺ Metabolism as a Core Biochemical Phenotype of Aging

To establish the role of NAD⁺ metabolism in aging, we compared PARP activity (global PARylation), NAD⁺ levels and sirtuin activation in young versus old mice (24 and 103 weeks) (Houtkooper et al., 2011). Both in liver and muscle of aged mice, PARylation was markedly increased (Figure S1A available online). In line with the hypothesis that PARP proteins are major NAD⁺ consumers, NAD⁺ levels were robustly decreased in older mice (Figure S1B), confirming recent data (Braidy et al., 2011; Yoshino et al., 2011). Changes in NAD⁺ are generally translated into altered SIRT1 activity (reviewed in Houtkooper et al., 2012). As NAD⁺ levels in aged mice were indeed reflected in the NAD⁺-signaling network in aging is evolutionarily conserved (Figure 2.1), supplementation with PARP inhibitors or NAD⁺ precursors significantly increased NAD⁺ levels (Figures 2E, S3A, and S3B). Although the role of SIRT1 or its homologs in lifespan extension under basal, unstressed, conditions is subject of debate (Burnett et al., 2011; Rogina and Helfand, 2004; Tissenbaum and Guarente, 2001; Viswanathan and Guarente, 2011), it holds a central position in healthspan regulation in the context of disease or cellular stress (Houtkooper et al., 2012). Given the NAD⁺ dependence of sirtuin enzymes (Imai et al., 2000), we analyzed epistasis by treating mutant worms with the PARP inhibitor AZD2281 or the NAD⁺-dependent of the lifespan extension induced by two distinct strategies to raise NAD⁺ levels.

PARP Inhibitors and NAD⁺ Precursors Boost Mitochondrial Function

As NAD⁺ and SIRT1/sir-2.1 are thought to influence oxidative metabolism (Guarente, 2008; Houtkooper et al., 2012), we functionally characterized mitochondrial activity in AZD2281- and NR-treated worms by measuring oxygen consumption rates. Although respiration strongly decreased with age in control worms, worms treated with AZD2281, NR, and NAM maintained or even increased respiration at young adult level (Figures 2G and S3C). This was corroborated by increased mitochondrial abundance evaluated by the mtDNA/nDNA ratio (Figure 2H), increased ATP levels (Figure 2I), and increased gene expression of enzymes controlling key metabolic pathways, e.g., the TCA cycle gene citrate synthase (cts-1), the glycolysis gene hexokinase (hjk-1), and the gluconeogenesis gene pyruvate carboxylase (pyc-1) (Figure 2J). Functionally, the improved metabolic state was accompanied by better
Figure 1. NAD⁺ Is Causally Involved in Aging

(A) Aged C. elegans displayed higher total protein PARylation levels, which were largely attenuated in pme-1 mutants. Ponceau staining is used as a loading control.

(B) Aging decreased worm NAD⁺ levels, in both wild-type and in pme-1 mutant worms, with a higher level of NAD⁺ in the pme-1 mutant during aging. Two-way ANOVA indicated significant difference with age (p < 0.008) and genotype (p = 0.02).

(C) pme-1 mutant worms accumulated less of the aging pigment lipofuscin compared to wild-type worms.

(D and E) Supplementation of N2 wild-type worms with 4 mM paraquat depletes NAD⁺ levels (D) and shortens lifespan (E).

(F and G) RNAi against qns-1, encoding NAD⁺ synthase, depletes NAD⁺ levels (F) and shortens lifespan in worms (G).

(H) pme-1(ok988) mutant worms show a 29% mean lifespan extension (left), whereas pme-1 RNAi in the rrf-3(pk1426) strain extends lifespan by 20% (right).

(I and J) PARP inhibition by either AZD2281 (100 nM) or ABT-888 (100 nM) extended worm lifespan, respectively, by 22.9% (I) and 15% (J).

(K) The lifespan extension of AZD2281 is pme-1-dependent.

Bar graphs are expressed as mean ± SEM, *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001. For lifespan curves, p values are shown in the graph (n.s. = not significant).

See also Figures S1, S2A, and S2B. See Tables S1 and S2 for additional detail on the lifespan experiments.
It is unclear whether, and if so how, these two “mitochondrial aging” pathways are activated by NAD+ and how they are intertwined, although it was already shown that ROS do not cause

**Mitochondrial Theories of Aging**

Two pathways have been described to link mitochondrial activity and aging, UPRmt and the reactive oxygen species (ROS) defense pathway. UPRmt is activated when protein balance in mitochondria is disturbed. This occurs, for instance, upon accumulation of misfolded or unfolded proteins (Haynes and Ron, 2010). Alternatively, disturbance of the delicate balance between mitochondrial protein production from nDNA and mtDNA—a state we termed mitonuclear protein imbalance—is associated with UPRmt activation (Houtkooper et al., 2013). This triggers a mitochondrial-to-nuclear stress-signaling pathway, which induces the transcription of nDNA-encoded mitochondrial molecular chaperones, such as mtHSP70, HSP60, and HSP10 and the protease CLPP (Durieux et al., 2011; Yoneda et al., 2004; Zhao et al., 2002). On the other hand, the defense against the accumulation of ROS is activated when altered mitochondrial activity causes formation of excessive oxygen radicals, with the ultimate goal of preventing damage of the (sub)cellular microenvironment, e.g., lipids, DNA, and proteins. This pathway involves the nuclear translocation of the FOXO transcription factor daf-16 (Berdichevsky et al., 2006), which, among other targets, induces the transcription of the mitochondrial antioxidant sod-3 (Honda and Honda, 1999). The mammalian daf-16 homolog FOXO3A has been described as a deacetylation target for SIRT1 in mammals (Brunet et al., 2004; Motta et al., 2004; van der Horst et al., 2004), and daf-16 was shown to interact with sir-2.1 (Berdichevsky et al., 2006; Hashimoto et al., 2010), providing a possible link between NAD+ and this pathway.

It is unclear whether, and if so how, these two “mitochondrial aging” pathways are activated by NAD+ and how they are intertwined, although it was already shown that ROS do not cause

**Figure 2. PARP Inhibitors and NAD+ Precursors Increase Mitochondrial Function**

(A and B) Supplementation of the NAD+ precursor NR (500 μM) or NAM (200 μM; B) in wild-type N2 worms increases lifespan. (C) Combined treatment using optimal concentrations of AZD2281 (100 nM) and NR (500 μM) extends lifespan (+16%/p = 0.01), whereas the individual compounds at these concentrations had no effect on lifespan (+7%/n.s. and +5%/n.s., respectively). Mean lifespans: vehicle: 16.1 ± 0.7 days; 100 nM AZD2281: 19.7 ± 0.8 days; 500 μM NR: 18.7 ± 0.8 days; 100 nM AZD2281+500 μM NR: 18.6 ± 0.7 days. (D) A combination of sub-optimal doses of AZD2281 (10 nM) and NR (100 μM) extended lifespan (11%/p = 0.011), whereas the individual compounds at these concentrations had no effect on lifespan (+7%/n.s. and +5%/n.s., respectively). Mean lifespans: vehicle: 20.1 ± 0.6 days; 10 nM AZD2281: 21.5 ± 0.7 days; 100 μM NR: 18.2 ± 0.7 days. (E) AZD2281 and NR supplementation increased mitochondrial O2 consumption, ATP content, and mRNA levels in C. elegans.

See also Figures S2C, S2D, and S3. See Tables S1 and S2 for additional detail on the lifespan experiments.

Worm motility at later age (Figure 2K), a sign of improved fitness with age.
sod-3

At day 1, AZD2281 and NR cause a burst of ROS, as measured using the MitoSOX probe. This was not accompanied by an induction of the antioxidant gene sod-3 (measured using a GFP-coupled sod-3 reporter). See also Figure S4. See Table S1 for additional detail on the lifespan experiments.

UPRmt

At day 1 of adulthood, AZD2281 and NR reduced the expression of mitochondrial fusion genes fzo-1 and opa-1, without affecting the fission gene drp-1. (G and H) RNAi of the UPRmt regulator ubl-5 abrogated the lifespan extension induced by AZD2281 (G; at 100 nM) and NR (H; at 500 μM). (I) The UPRmt induction by AZD2281 and NR at day 1 is also ubl-5-dependent.

Early Phase Activation of UPRmt by NAD+ Boosters

By using confocal microscopy in the pmryo-3::mito::GFP reporter, which expresses mitochondria-targeted GFP in the muscle, we determined the morphology and intensity of the mitochondrial network. At day 1 of adulthood, AZD2281 or NR treatment led to a dense mitochondrial network that appears to be more fragmented compared to vehicle control worms (Figure 3A). This reticular network was likely caused by reduced expression of the mitochondrial fusion genes fzo-1 and opa-1, without changes in the fission regulator drp-1 (Figure 3B). We then measured the two prime mitochondrial pathways involved in aging, ROS and UPRmt. ROS was measured using

Figure 3. Early Phase Response of NAD+ Boosters on Mitochondrial Aging Pathways

(A) The effects of AZD2281 (100 nM) and NR (500 μM) on mitochondrial content and morphology in body wall muscle. At day 1 of adulthood, mitochondria of AZD2281- or NR-treated worms appear more fragmented. Stars represent nuclei, insets show higher magnification of a small section of the image, marked by dashed rectangle.

(B) At day 1 of adulthood, AZD2281 and NR reduced the expression of mitochondrial fusion genes fzo-1 and opa-1, without affecting the fission gene drp-1. (C) At day 1, AZD2281 and NR cause a burst of ROS, as measured using the MitoSOX probe. This was not accompanied by an induction of the antioxidant gene sod-3 (measured using a GFP-coupled sod-3 reporter).

(D and E) At day 1, AZD2281 and NR induced the mitochondrial unfolded protein response (UPRmt) (Durieux et al., 2011). We hence set out to perform a detailed temporal analysis of the activation of both stress pathways, focusing on day 1 and day 3 of adulthood. These days were selected based on the premise that they are in different phases of the mitohormesis response (Mouchiroud et al., 2011; Schulz et al., 2007; Zarse et al., 2012). Mitohormesis refers to the concept that an adaptive and protective antioxidant response is activated in mitochondria by an initial accumulation of moderate levels of potentially toxic ROS. Although day 1 is the first day of adulthood and coincides with a burst in ROS production, day 3 is the late reproductive phase (but still pre-aging) and is characterized by activated ROS defense (Schulz et al., 2007).
the mitoSOX probe, which indicates specific mitochondrial superoxide burst production. Both AZD2281 and NR induced a strong superoxide burst at day 1 of adulthood, although at this stage no protective activation of sod-3 expression was observed (Figure 3C). When we measured at the same age UPRmt activation using hsp-6::GFP reporter worms (Yoneda et al., 2004), both compounds robustly induced UPRmt (Figure 3D), without activating the ER-specific unfolded protein response (hsp-4::GFP; Figure 3E). Importantly, the induction of UPRmt, but not sod-3, was confirmed in worms treated with pme-1 RNAi, confirming that the effect is not due to off-target effects of the drugs (Figure S4A). The precocious activation of UPRmt after AZD2281 or NR treatment was associated with mitonuclear protein imbalance, as evidenced by the decreased ratio between the nDNA-encoded ATP5A and the mtDNA-encoded MTCO1 (Figure 3F).

We next tested whether UPRmt was essential for longevity induced by NAD+ boosters or PARP inhibitors. We used worms treated with RNAi directed against the UPRmt gene, ubl-5, an essential component of the mitochondria-to-nucleus feedback (Durieux et al., 2011). Indeed, ubl-5 RNAi abrogated the lifespan extension conferred by both AZD2281 and NR treatment (Figures 3G and 3H). This coincided with the attenuation of UPRmt activation in ubl-5 RNAi worms (Figure 3I). These data suggest that UPRmt is an early-phase response induced by increased NAD+ levels.

### Late-Phase Activation of ROS Defense by NAD+ Boosters

To test for potential adaptive responses with respect to ROS and UPRmt, we measured similar parameters at day 3 of adulthood. Although fragmented at day 1, mitochondria appear hyperfused at day 3 (Figure 4A), which, at this time, is now associated with increased gene expression of fzo-1 and opa-1 (Figure 4B). When we analyzed the activation of UPRmt and ROS defense at day 3 of adulthood, we not only observed a continued activation of UPRmt, but now, unlike the situation at day 1, also a strong activation of the sod-3 promoter in worms treated with AZD2281, NR (Figure 4C), or pme-1 RNAi (Figure S4B). We then characterized the ROS defense mechanisms in more detail. At day 3, the higher sod-3::GFP levels after AZD2281 or NR treatment were not due to increased daf-16 gene expression, a key transcriptional regulator of antioxidant defense (Figure 4D). The absence of an induction of the daf-16 gene suggests that daf-16 activity might be regulated by AZD2281 and NR via changes in subcellular distribution rather than transcription (Alam et al., 2010). Strikingly, the stress responses were specific for sod-3 and UPRmt, as expression of cytosolic or ER UPR markers, as well as other antioxidants did not change, or even decrease (Figure 4E).

Considering the strong induction of sod-3 expression, we next tested whether AZD2281 and NR could protect against the premature aging caused by the ROS-inducer paraquat. Although vehicle-treated worms die young (median = 6 days), AZD2281-, NR-, or NAM-treated worms survive significantly longer (median = 7 days) (Figures 4F and S5A). As mentioned above, DAF-16 activity is primarily regulated by its subcellular localization (Alam et al., 2010). We hence used the daf-16::GFP reporter strain to establish DAF-16 localization at day 3 following AZD2281, NR, or NAM exposure. In line with the increased sod-3 transcriptional activation (Figure 4C), daf-16 appeared in a more punctate pattern consistent with its nuclear localization that is required for it to activate transcription of its antioxidant target genes (Figures 4G and S5B). Quantitative analysis of this daf-16 translocation after these various stimuli shows that approximately two to three times more daf-16 is localized in the nucleus (Figures 4H and SSC). Confirming the crucial role of daf-16, we observed that the lifespan extension induced by compounds that enhance NAD+ levels was strictly dependent on the expression of daf-16 (Figure 4I), suggesting that the induction of antioxidant defense is key for AZD2281 and NR to grant longevity. Finally, the induction of sod-3 expression was dependent on the presence of the UPRmt regulator ubl-5 (Figure 4J), suggesting that this UPRmt is involved in the transcriptional activation of antioxidants as well.

### UPRmt Controls Lifespan Extension by sir-2.1 Overexpression

The role of sir-2.1 in lifespan regulation is debated. Although original reports claimed that overexpression of sir-2.1 led to strong lifespan extension (Tissenbaum and Guarente, 2001), this was later shown to be partly due to an unlinked mutation affecting sensory perception (Burnett et al., 2011; Viswanathan and Guarente, 2011). Interestingly, when the unintended mutation was lost by genetic outcrossing, the resulting MV389 sir-2.1 transgenic worm strains maintained an ~10% lifespan extension (Viswanathan and Guarente, 2011). We used this sir-2.1 transgenic worm strain to test whether increased lifespan due to enhanced sirtuin expression involves UPRmt. The MV389 worms lived 25% longer compared to isogenic controls (Figure 5A) and displayed a robust sir-2.1 overexpression that could be abrogated using RNAi (Figure 5B). Supplementation of NR in MV389 worms did not further extend lifespan (Figure 5A). The fact that the MV389 worms lived slightly longer in our study compared to previous data (Viswanathan and Guarente, 2011) is due to small differences in our technical approach, as we now censored worms with a protruding vulva phenotype. Similar to compounds that boost NAD+ levels, sir-2.1 overexpression did not affect the daf-16 gene expression, but increased expression of mitochondrial regulators cts-1 and fzo-1, the daf-16 target sod-3, and the expression of the UPRmt gene hsp-6, without changes in other stress markers, such as hsp-4, hsf-1, sod-1, sod-2, gst-4, and prdx-2 (Figure 5C). MV389 worms also displayed mitonuclear protein imbalance with a relative decrease in the ratio between nDNA-encoded ATP5A and mtDNA-encoded MTCO1 (Figure 5D). The longevity of MV389 worms was fully dependent on sir-2.1 and daf-16, as RNAi against these genes completely abrogated the lifespan extension (Figures 5E and 5F). Importantly, sir-2.1 knockdown in MV389 was also sufficient to block the induction of the UPRmt gene hsp-6 (Figure 5G). In line with this observation, crossing the sir-2.1 transgenic worms with the hsp-6::GFP UPRmt reporter strain confirmed the robust induction of UPRmt (Figures 5H and 5I), which was attenuated by RNAi targeting sir-2.1 or the UPRmt regulator ubl-5 (Figure 5I), indicating an epistatic link between sir-2.1 expression and the UPRmt pathway. Consistent with this link, ubl-5 RNAi almost completely restored the lifespan of the MV389 strain to wild-type levels, showing that the effects of sir-2.1 overexpression were also fully dependent on UPRmt (Figure 5J).
Increased NAD+/SIRT1 Signaling Induces UPR\textsuperscript{mt} in Mammalian Cells

We next aimed to confirm the physiological relevance of the NAD+/SIRT1/UPR\textsuperscript{mt}/SOD signaling axis in mammalian cells. In line with our previous results in mice (Bai et al., 2011b; Canto et al., 2012), both PARP inhibition and supplying NAD\textsuperscript{+} precursors for 48 hr in the hepatocyte cell line AML12 increased the mtDNA/nDNA ratio (Figures 6A and 6B, upper), demonstrating mitochondrial biogenesis. Similar to worms at day 3, biogenesis was accompanied by induction of the mitochondrial fusion gene Mfn2 (Figures 6A and 6B, lower). Furthermore, AZD2281 and NR dose-dependently induced gene expression of the mammalian UPR\textsuperscript{mt} homolog Hsp60, as evidenced using a luciferase reporter controlled by the human Hsp60 promoter (Figures 6C and 6D). At the protein level, AZD2281 and NR induced the UPR\textsuperscript{mt} protease CLPP (Figures 6E–6H). A detailed time course analyses showed that this UPR\textsuperscript{mt} response was induced after 12 hr (Figures 6E–6H) and coincides with the induction of mitonuclear protein imbalance, reflected by the ratio between nDNA-encoded SDHA versus the mtDNA-encoded MTCO1 (Figures 6 E–6H).

Interestingly, the expression of SOD2—the mammalian ortholog of worm sod-3—also increased, but whereas SOD2 protein

---

**Figure 4. Late-Phase Effects of NAD\textsuperscript{+} Boosters on Mitochondrial Aging Pathways**

(A) The effects of AZD2281 (100 nM) and NR (500 μM) on mitochondrial content and morphology in body wall muscle. At day 3 of adulthood, mitochondria of AZD2281- or NR-treated worms appear more fused. Stars represent nuclei, insets show higher magnification of a small section of the image, marked by dashed rectangle.

(B) At day 3 of adulthood, AZD2281 and NR increased the expression of mitochondrial fusion genes fzo-1 and opa-1, without affecting the fission gene drp-1.

(C) At day 3 of AZD2281 (100 nM) or NR (500 μM) treatment, UPR\textsuperscript{mt} is still activated (left), but now accompanied by an induction of the sod-3::GFP reporter (right).

(D and E) AZD2281- and NR-treated worms showed no change in daf-16 expression (D) or activation of expression of other stress genes (E).

(F) Supplementation of PARP inhibitor AZD2281 (100 nM) or NAD\textsuperscript{+} precursor NR (500 μM) increases mean lifespan of wild-type N2 worms treated with 4 mM paraquat. p Values are shown in the graph.

(G) Representative images of daf-16::GFP reporter worms treated with either vehicle or AZD2281 (upper)/NR (lower), showing nuclear accumulation of daf-16 following treatment, indicated by arrowheads.

(H) Quantification of daf-16 nuclear translocation following treatment with AZD2281 (upper), NR (lower). Localization is shown as percentage of worms that shows nuclear (yellow or light blue) or cytosolic (red or dark blue) localization.

(I) Lifespan extension following AZD2281 or NR treatment is dependent on daf-16.

(J) The induction of sod-3::GFP reporter following AZD2281 or NR treatment is dependent on the UPR\textsuperscript{mt} regulator ubl-5.

Bar graphs are expressed as mean ± SEM, *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.

See also Figures S4 and S5. See Table S1 for additional detail on the lifespan experiments.
expression trended up 6 hr after starting the treatment (Figures 6E–6H), it was only after 24 hr that both protein level and SOD activity were significantly increased (Figures 6I and 6J), possibly because activity of SOD2 is also regulated by posttranslational modifications such as acetylation (Houtkooper et al., 2012). The late response of SOD2 is reminiscent of the induction of sod-3 in worms, which is also trailing the primary induction of UPR mt (Figures 3C, 4D, and 4C).

Finally, we assessed mitonuclear protein imbalance and UPR mt activation in primary mouse hepatocytes in which SIRT1 expression was either enhanced or abrogated. Similar to sir-2.1 transgenic worms, primary hepatocytes in which Sirt1 was overexpressed by an adenoviral vector (ad-Sirt1) showed mitonuclear protein imbalance, i.e., decreased ratio between ATP5A (encoded by nDNA) and MTCO1 (by mDNA), associated with UPR mt induction—as evidenced by the robust increase in CLPP and HSP60 protein expression—and SOD2 expression, relative to control (Ad-GFP transduced) hepatocytes (Figure 7A). We then aimed to analyze the effect of treating wild-type hepatocytes with AZD2281 or NR, either in the presence or absence of Sirt1. To this end, we isolated hepatocytes from floxed Sirt1L2/L2 mice (Sirt1+/−). These were subsequently infected with either ad-GFP control (Ad-GFP transduced) hepatocytes (Figure 7A).

Bar graphs are expressed as mean ± SEM, *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001. See Table S1 for additional detail on the lifespan experiments.
Figure 6. NAD⁺ Boosters Activate UPRmt in Mammalian Cells

(A and B) Treatment with NR (A; 1 mM) or AZD2281 (B; 1 μM) increases the ratio between mitochondrial DNA (mtDNA) and nuclear DNA (nDNA), a common marker for mitochondrial abundance in the AML12 hepatocyte cell line (upper). This increase reflects induced mitochondrial biogenesis. At the same time, NR and AZD2281 induce the expression of the mitochondrial fusion gene Mfn2 (lower).

(C and D) AZD2281 and NR dose-dependently activate the transcription of a human Hsp60 promoter luciferase reporter, transfected into AML12 cells. (E–H) The NAD⁺ precursor NR (E and G; 1 mM) and the PARP inhibitor AZD2281 (F and H; 1 μM) induce UPRmt, as evidenced by CLPP expression, in a time-dependent fashion in AML12 cells. The mitochondrial antioxidant SOD2 also increased over time. HSP90 is a cytosolic stress marker that is not affected by treatment with AZD2281 or NR. NR and AZD2281 also induced marked mitonuclear protein imbalance, as evidenced by the ratio SDHA/MTCO1 (nDNA- and mtDNA-encoded, respectively). Actin served as a loading control. (G and H) Quantifications of the western blots in (E) and (F).

(I and J) At the later stages following NR (I) or AZD2281 (J) treatment, SOD activity was increased. The fact that activity trails behind protein expression may be due to posttranslational modifications regulating SOD2 activity. Bar graphs are expressed as mean ± SEM, *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.

(Figure 7A), wild-type primary hepatocytes (ad-GFP) that were treated with AZD2281 or NR displayed mitonuclear protein imbalance—i.e., decreased ratio between nDNA- and mtDNA-encoded OXPHOS proteins—increased UPRmt (CLPP and HSP60) and increased SOD2 expression, whereas these effects were completely blocked in the ad-Cre infected Sirt1 floxed hepatocytes (Figure 7B). Altogether, these data validate the conservation of the NAD⁺/SIRT1/UPRmt/SOD signaling pathway in mammals, as well as the role of mitonuclear protein imbalance therein.

DISCUSSION

The progressive functional decline that happens during the normal aging process is associated with the accumulation of mutations in DNA (Hoeijmakers, 2009) and changes in metabolic rate and mitochondrial function (Houtkooper et al., 2011). How these DNA damage and mitochondrial metabolism pathways are intertwined is starting to be elucidated, but the mechanistic basis remains poorly understood. Key players in both these pathways include the sirtuin and PARP proteins, both NAD⁺-dependent enzymes, and considerable prior knowledge to support a role of these pathways with respect to age-related metabolic diseases has accumulated. For instance, the increased NAD⁺ levels in Parp1⁻/⁻ or Cd38⁻/⁻ mice and in mice treated with the NAD⁺ precursors NR or NAM, led to SIRT1-dependent improved mitochondrial function, protecting them against the metabolic damage induced by high-fat diets (Bai et al., 2011b; Barbosa et al., 2007; Cantó et al., 2012; Yoshino et al., 2011). Conversely, reduced levels of NAD⁺ metabolism were observed in aged rats and mice (Braidy et al., 2011; Yoshino et al., 2011), although no mechanistic explanation of this observation was presented.

We hence set out to investigate the causal link between NAD⁺ and aging, whether increasing NAD⁺ levels and sirtuin activity are sufficient to prevent aging and if so, which downstream aging pathways are involved. We primarily used the nematode C. elegans as it allows detailed genetic interventions coupled to full lifespan analysis. Additionally, we set up a range of mammalian, cell-based studies to complement our C. elegans results. Our data indicate that PARP activity, by modulating NAD⁺ availability, regulates mitochondrial biogenesis and as such plays an important role to preserve mitochondrial and organismal fitness. Not only is PARylation increased and are NAD⁺ levels reduced in aged worms and mice, but we also show that depleting NAD⁺ levels, either chemically using paraquat or genetically by inhibiting the NAD⁺ synthase qns-1, is sufficient to shorten worm lifespan. Conversely, interventions aimed to safeguard NAD⁺ levels curb the aging process and extend lifespan in C. elegans. Two independent strategies were used to boost NAD⁺ levels, i.e., mutation/RNAi (pme-1) or inhibition (AZD2281 or ABT-888) of the NAD⁺-consuming PARP enzymes and supplementation of NAD⁺ precursors (NR or NAM). The fact that both these approaches to raise NAD⁺ levels promote
a similar phenotype strengthens the hypothesis that NAD\(^+\) is a critical metabolite influencing mitochondrial fitness and lifespan in a \(sir-2.1\)-dependent way. Also, because NAD\(^+\) precursors and \(sir-2.1\) overexpression are unlikely to modify the PARylation status of proteins or DNA directly, this excludes PARylation as a causal contributor of aging. Although the role of \(sir-2.1\) in longevity is subject of debate (reviewed in Houtkooper et al., 2012) our data provide unequivocal evidence in support of its importance in lifespan regulation.

Two aging pathways are known to play a role in the mitochondrial theory of aging, UPR\(^{mt}\) and ROS (Durieux et al., 2011; Sena and Chandel, 2012). In worms that accumulated NAD\(^+\) or in which \(sir-2.1\) is overexpressed, we observed a marked induction of UPR\(^{mt}\), as well as improved ROS defense. Based on our time course experiments in worms and its \(ubl-5\) dependence, we concluded that the initial phase is characterized by a burst in ROS and induction of UPR\(^{mt}\), which is associated with a state we termed mitochondrial protein imbalance, referring to the altered balance between nDNA- and mtDNA-encoded OXPHOS subunits. This suggests that, when nDNA-encoded protein synthesis is not matched by mtDNA-encoded protein synthesis, UPR\(^{mt}\) is activated to provide protective effects. We demonstrated that the UPR\(^{mt}\) regulator \(ubl-5\) is essential for the lifespan extension inferred by either increasing NAD\(^+\) levels or by \(sir-2.1\) overexpression.

Besides UPR\(^{mt}\), the NAD\(^+\) boosting strategies, using either the PARP inhibitor AZD2281 or the NAD\(^+\) precursors NR and NAM, also induced an antioxidant response. Following an early-phase burst in ROS, DAF-16 translocated to the nucleus, activated expression of the key mitochondrial antioxidant sod-3, and likely involves the \(sir-2.1\)/daf-16 signaling pathway (Berdichevsky et al., 2006; Hashimoto et al., 2010). Interestingly, although it was previously shown that ROS are not critically involved in the induction of UPR\(^{mt}\) (Durieux et al., 2011), our data demonstrate that the converse may apply, i.e., blocking UPR\(^{mt}\) through \(ubl-5\) RNAi is sufficient to block a further induction the antioxidant response. Although further work is needed to establish how UBL-5 controls sod-3 expression, the combined activation of UPR\(^{mt}\) and ROS defense results in protection against age-related decline and lifespan extension, at least in worms (Figure S6). We confirmed this link also in mammals. PARP inhibitors (Bai et al., 2011b) and NAD\(^+\) precursors (Cantó et al., 2012; Yoshino et al., 2011) have been reported to increase NAD\(^+\) levels, activate sirtuins and induce mitochondrial biogenesis through PGC-1\(\alpha\) in mammals (Cantó et al., 2009; Rodgers et al., 2005). Here, we showed that AZD2281 and NR, but also \(sir-2.1\) overexpression, likewise induced a robust UPR\(^{mt}\) and ROS defense in mammals, underscoring the essential and conserved nature of this dual stress response.

Our results expose an evolutionarily conserved pathway by which NAD\(^+\)/sirtuin activity leads to UPR\(^{mt}\), a \(sir-2.1\) signaling pathway, that in parallel to the established daf-16/sod-3 antioxidant defense (Berdichevsky et al., 2006), improves metabolic health and extends lifespan. We expect that other sirtuin activating compounds may also induce UPR\(^{mt}\). Indeed, data from our lab indicates that resveratrol requires UPR\(^{mt}\) activation to extend lifespan (Houtkooper et al., 2013). Altogether, the data in the worm assembled in this study validate a link between NAD\(^+\), sirtuins, UPR\(^{mt}\), antioxidants, and lifespan control. Furthermore, our results in mammalian cell-based systems suggest that the mechanisms underlying NAD\(^+\)/\(sir-2.1\)/UPR\(^{mt}\)/SOD signaling pathway are conserved and may open up the opportunity for preventive and/or therapeutic use of this pathway in the context of aging and aging-related disorders.

**EXPERIMENTAL PROCEDURES**

**C. elegans Experiments**

C. elegans strains were cultured at 20°C on nematode growth media agar plates seeded with *Escherichia coli* strain OP50 unless stated otherwise. Strains were provided by the Caenorhabditis Genetics Center (University of Minnesota) and detailed in the Extended Experimental Procedures. Worm lifespan tests were performed as described (Mouchiroud et al., 2011). Briefly, 60–100 animals were used per conditions and scored every other day.
Treatments with PARP inhibitors—AZD2281 and ABT-888—or NAD+ precursors—nicotinamide riboside (NR) and nicotinamide (NAM)—were added at the indicated concentration just before pouring the plates. Animals were exposed to compounds during the entire life from eggs until death.

**Mammalian Experiments**

Primary hepatocytes were isolated from Sirt1-1/2/L2 (see more details in Extended Experimental Procedures) and transduced either with an Ad-GFP or an Ad-Cre virus at a MOI = 5 to generate matched Sirt1-/-/- (wild-type) and Sirt1-/-/- (knockout) hepatocytes, respectively. After overnight infection, culture medium was removed and Sirt1-/-/- and Sirt1-/-/- hepatocytes cultures were treated or not with NR or AZD2281. To obtain gain-of-Sirt1-function hepatocytes, Ad-mSirt1 (adgene 8438) or Ad-GFP virus was used at the same MOI to infect primary hepatocytes obtained from a male C57BL/6J mouse to generate hepatocytes overexpressing Sirt1 and GFP (control hepatocytes), respectively. Mouse experiments were performed in accordance with Swiss law and institutional guidelines.

**Worm- and Cell-Based Assays**

Worm oxygen consumption was measured using the Seahorse XF96 equipment (Seahorse Bioscience). Worms were transferred in 96-well standard Seahorse plates (ten worms/well) and oxygen consumption was measured six times. Respiration rates were normalized to the number of worms in each individual well. Gene expression (RT-qPCR, primer sequences in Table S3), protein expression (western blot), mtDNA copy number, and ROS assays were performed following routine procedures, as outlined in the Extended Experimental Procedures.

**Statistics**

Survival analyses were performed using the Kaplan-Meier method and the significance of differences between survival curves calculated using the log rank test. Differences between two groups were assessed using two-tailed t tests. To compare the interaction between age and genotype, two-way ANOVA tests were performed. Analysis of variance, assessed by Bonferroni multiple comparison test, was used when comparing more than two groups. We used R (software version 2.9.0) for the calculation of mean lifespan and SEM and GraphPad Prism 5 (GraphPad Software) for all other statistical analyses. All p values < 0.05 were considered significant.

**SUPPLEMENTAL INFORMATION**

Supplemental Information includes Extended Experimental Procedures, six figures, and three tables, and can be found with this article online at http://dx.doi.org/10.1016/j.cell.2013.06.016.

**ACKNOWLEDGMENTS**

We thank Pierre Gáneczky for sharing reagents and equipment, the Caenorhabditis Genetics Center for providing worm strains, and the Auwerx team for discussions. L.M. is supported by the “Fondation pour la Recherche Médicale” and R.H.H. by a VENI grant from ZonMw (number 91613050) and an AMC ditis.

**ACKNOWLEDGMENTS**

We thank Pierre Gáneczky for sharing reagents and equipment, the Caenorhabditis Genetics Center for providing worm strains, and the Auwerx team for discussions. L.M. is supported by the “Fondation pour la Recherche Médicale” and R.H.H. by a VENI grant from ZonMw (number 91613050) and an AMC postdoctoral fellowship. J.A. is the Nestlé Chair in Energy Metabolism. This work is supported by grants from the Ecole Polytechnique Fédérale de Lausanne, EU Ideas program (ERC-2008-AdG-23138), NIH (R01HL106511-01A and R01AG043930), Velux Stiftung, and Swiss National Science Foundation (31003A-124713, 31003A-125487, and CRSII3-136201).

Received: November 15, 2012
Revised: April 25, 2013
Accepted: June 11, 2013
Published: July 18, 2013

**REFERENCES**


